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ABSTRACT 
Mesenchymal stem cells (MSCs) are present in vascular structure and play an important role 
in vessel remodeling in normal, as well as pathological conditions, such as transplant 
arteriosclerosis or tumor angiogenesis. Moreover, MSCs affect tumor growth and metastasis 
by production of chemokines, such as (C-C motif) ligand 7 (CCL7). Similar effect on tumor 
biology exert multiple other factors, such as CCAAT-enhancer binding protein β (C/EBPβ), 
which is a transcription factor playing an essential role in mammary gland development and 
breast cancer progression.  
In study I, presence of MSCs in vascular structure, as well as their role in vascular 
remodeling in transplant arteriosclerosis was analyzed. Specifically, rat allograft model was 
used to identify the predominant cell types associated with this process and to find factors 
crucial for their recruitment into the graft. This study identified adventitia as a potentially 
important source of mesenchymal stem cells that contribute to formation of intimal 
hyperplasia. Furthermore, monocyte chemoattractant protein-1 (MCP-1) was found as a 
potent chemokine for the recruitment of adventitial vascular progenitor cells to intimal 
lesions. 
Study II and III focus on the role of C/EBPβ transcription factor in breast cancer 
progression. Namely, in study II C/EBPβ was associated with epithelial-to-mesenchymal 
transition (EMT) features in triple-negative human breast cancer and invasive areas of 
mammary tumors in MMTV-PyMT mice. In vitro studies showed that C/EBPβ was repressed 
during EMT by miR-155, a breast cancer oncomiR. Moreover, C/EBPβ depletion enhanced 
TGFβ response towards EMT and contributed to evasion of growth inhibitory response to 
TGFβ. C/EBPβ loss caused potentiated invasion and metastasis of breast cancer cells to the 
lungs in mouse 4T1 model. In addition, C/EBPβ was shown to transcriptionally activate 
genes encoding epithelial junction proteins E-cadherin and coxsackie virus and adenovirus 
receptor (CAR). Study III was focused on explaining the mechanism of C/EBPβ effect on 
metastasis, as well as determining the relationship between C/EBPβ expression and survival 
of breast cancer patients. Firstly, study showed that decrease in C/EBPβ expression was 
associated with shorter overall survival of breast cancer patients. Next, loss of C/EBPβ 
affected tumor growth, morphology and lung metastasis in murine 4T1 breast cancer model. 
Moreover, inhibition of C/EBPβ caused enhanced histocompatibility complex II (MHCII) 
expression and accumulation of CD45+, CD3+ and CD4+ lymphocytes in the tumors. 
Additional experiments confirmed the role of inflammation in C/EBPβ-mediated metastasis 
formation. 
Study IV involved analysis of crosstalk between MSCs and colon cancer. Results 
demonstrated that MSCs affect CT26 tumor cell proliferation, migration and expression of 
different chemokines in coculture with CT26 cells in vitro, such as (C-C motif) ligand 7 
(CCL7). The next goal of the study was to analyze the effect of CCL7 overexpression on 
tumor progression in mouse CT26 colon cancer model. Cells overexpressing CCL7 
accelerated early phase of tumor growth and led to higher lung metastasis rate in tumor-
bearing mice. Lastly, higher CCR2 expression, which is a CCL7 receptor, was associated 
with shorter overall survival of colorectal cancer patients. 
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1 INTRODUCTION 
1.1 BLOOD VESSELS 
Blood vessels provide circulatory system for the nutrients and oxygen in the body, ensuring 
normal tissue function. All vessels except for the capillaries contain three layers: tunica intima, 
tunica media and tunica adventitia (Fig. 1). Tunica intima, the thinnest layer in the vessel, is 
composed of a single sheet of squamous endothelial cells covering the lumen, which are 
surrounded by elastic connective tissue called internal elastic lamina. Endothelial cells rest on a 
basement membrane composed of extracellular matrix proteins, such as collagen type IV, heparin 
sulfate proteoglycans and laminin 1. Tunica media is rich in vascular SMCs and represents the 
thickest layer in the arteries. SMCs not only produce multiple ECM components (collagen, elastic 
etc.), but also regulate the caliber of the blood vessels in the body and thus, affect local blood 
pressure. Tunica adventitia is usually thickest layer in the veins and entirely comprises of loose 
connective tissue containing mainly collagenous and elastic fibres, fibroblasts and macrophages. 
Additionally, it involves nerves supplying the vessels and nutrient capillaries (vasa vasorum) in 
case of larger blood vessels. Adventitia has been shown to play a crucial role in vascular 
remodeling and development of vascular diseases, including atherosclerosis, transplant 
vasculopathy, hypertension as well as restenosis 2-4. 
 
Fig. 1 Structure of the arterial wall. 
1.1.1 Vascular remodeling  
Vascular remodeling is a complex process of structural changes caused by alterations in various 
cellular processes, such as cell growth, migration or ECM modifications and depends on the 
interplay between produced growth factors, vasoactive substances and hemodynamic stimuli 5. 
Even though remodeling is usually an adaptive response to long-term changes in hemodynamic 
conditions 6, it can also provide background for cardiovascular diseases, such as transplant 
arteriosclerosis, restenosis, atherosclerosis, hypertension or diabetes.  
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Vascular architecture can be altered in multiple manners dependent on different stimuli. For 
example, in response to increased pressure in the artery, the wall/lumen width ratio changes, at 
the same time enhancing vessel reactivity, what results in augmented peripheral resistance typical 
for hypertension 7. Reduced lumen diameter is also related to vascular remodeling in other 
diseases, such as restenosis after percutaneous intervention or cardiac allograft vasculopathy 6. 
Conversely, remodeling can also lead to higher lumen diameter and can compensate for increased 
plaque load 8. 
Vessel remodeling can also involve changes in the dimensions of the lumen, caused by active 
reorganization of wall components. Such alterations are observed in cases of vascular dilatation 
related to sustained high blood flow, what often occurs in patients with arteriovenous fistula and 
was shown in animal models 9, 10, as well as in case of cell apoptosis and matrix proteolysis 
leading to formation of aneurysm 11, 12. 
Moreover, blood vessels undergo remodeling as a result of different forms of vascular injury, 
including transplantation. Mechanical injury can result with vessel constriction and smaller 
vascular lumen in response to the scarring in the outer vessel layer. Main features of transplant 
vasculopathy include inflammation and formation of intimal hyperplasia. 
1.1.1.1 Intimal hyperplasia 
Intimal hyperplasia is associated with increased cell number and amount of ECM in the intimal 
layer of the vessel. Physiologically, it occurs during closure of ductus arteriosus 13, involution of 
the uterus 14 and aging of human aorta 15. Pathologically, intimal hyperplasia occurs in pulmonary 
hypertension 16, after balloon angioplasty 17, transplantation 18, in veins used as arteriovenous 
fistulas or artery bypass conduits 19 and finally, in pre-atherosclerotic lesions 20. 
Development of intimal hyperplasia requires a few essential stages. One of them is recruitment 
of inflammatory cells, such as macrophages and leukocytes, to an injured artery and mobilization 
of vascular progenitor cells from their niches. Platelets, activated endothelial cells, smooth muscle 
cells and macrophage foam cells produce platelet-derived growth factor (PDGF) and additional 
factors 1, which act as a chemoattractants enabling migration of phenotypically modified SMCs 
from the media into the neointima and their proliferation 21. Moreover, PDGF stimulates 
production of proteoglycans and collagen. At the same time, metalloproteinases (MMPs) cause 
remodeling of ECM, what further facilitates SMC migration and migration. Next, intima grows 
in response to cell proliferation, increased synthesis of ECM 21, progressive apoptosis and fibrosis 
in media.  
Cells forming neointima have been reported to originate from different sources. Namely, they can 
be derived from the adventitia, for example fibroblasts, pericytes, vascular progenitor cells 2, 22 or 
be circulating progenitor cells, such as bone marrow–derived cells, endothelial progenitor cells 
or smooth muscle progenitor cells 23-25. 
1.1.2 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are multipotent cells having ability to self-renewal and 
differentiation into several cell types, such as osteoblasts, chondrocytes, myocytes and adipocytes 
26. MSCs were first isolated and amplified from bone marrow in 1970 27. In order to standardize 
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isolation of human MSCs, The International Society for Cell therapy established a set of criteria, 
including adherence to plastic in in vitro culture, expression of a variety of surface markers, such 
as CD73, CD90, and CD105 in the absence of CD34, CD45, HLA-DR, CD14 or CD11b, CD79, 
or CD19 surface molecules as assessed by fluorescence-activated cell sorting analysis, and 
capacity to differentiate to osteoblasts, adipocytes, and chondroblasts in vitro 28. 
MSCs can be isolated from a variety of tissues, such as bone marrow 26, 29, adipose tissue 30, lung 
tissue 31, synovial tissue 32, umbilical cord blood 33 and peripheral blood 34. Even though they 
display different growth rates, they share capability to mesodermal differentiation and similar 
surface markers 35, 36. Moreover, the fact that MSCs have been isolated from several tissue types 
of adult mice, implicates the possibility that MSCs reside in all postnatal organs 37. 
MSCs were shown not only to differentiate into mesoderm-derived tissue, but also ectoderm-
derived tissue like astrocytes 38 or endoderm-derived cells and cardiomyocytes 39, 40. Apart from 
their differentiation properties, MSCs suppress proliferation of T-lymphocytes 41 and have ability 
to engraft, differentiate and contribute to functional recovery of ischaemic 42, 43, as well as 
infarcted 44 swine myocardium. Hence, MSCs have been used as a therapy in clinical trials for 
ischemic heart disease 45-47. 
Over the last decade, vascular biology field focused on analyzing the role of different progenitor 
cells, including mesenchymal stem cells in the formation of blood vessels 48. Blood vessels are a 
source of stem and progenitor cells, what affect various vascular processes and diseases 49. 
Furthermore, vessels are closely associated with stem cell niches regulating and protecting 
different stem and progenitor cells. Multiple studies have shown that mural cells, like smooth 
muscle cells or pericytes, are recruited to vessels from local areas 50-53.  
Since MSCs are important part of perivascular niche in several human organs 54 and coexpress 
similar markers as pericytes, discussion arose about the relationship between those cell types. 
Pericytes not only contribute to vessel stabilization by interactions with endothelial cells, but are 
a source of mesenchymal stem cells and differentiate into cells originating from mesenchyme 55.  
Increasing body of evidence supports association of vascular progenitor cells with intimal 
hyperplasia – a process of universal response of a vessel to injury 48, 56. Namely, Sca-1+ cells of 
adventitial origin have been shown to increase their number and proliferation rate during 
neointima formation in the injury model 57. Furthermore, MSCs and pericyte-like cells contribute 
to restenosis after arterial injury 58. In addition, adventitial progenitor cells are able to differentiate 
into SMCs that subsequently contribute to atherosclerosis of vein grafts in ApoE-deficient mice 
2. 
1.2 CANCER 
Cancer, also called malignant neoplasm, is one of the major health problems in the recent world. 
This term includes a broad group of diseases that cause loss of health and severe disability of the 
patients. It is characterized by uncontrollable cell growth and divisions, what leads to formation 
of malignant tumors and invasion to the other parts of the body. Invasion and metastasis do not 
happen in all tumor cases though, as some tumors, referred to as benign, do not cause distant 
metastasis. Invasive tumor cells might spread through the bloodstream or lymphatic system and 
form metastasis in different organs. 
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 In contrast to other cells, the growth of neoplastic cells is autonomous, excessive and 
disorganized. Typical hallmarks of cancer include: self-sufficiency in growth signals, apoptosis 
evasion, insensitivity to anti-growth signals, sustained angiogenesis, limitless potential and tissue 
invasion and metastasis (Fig. 2) 59.  
 
 
 
Fig. 2 Hallmarks of cancer according to Hanahan & Weinberg (modified) 59. 
There are several different types of malignancies that affect humans and they are classified based 
on the type of cell that the tumor cells resemble, which is hence assumed to be the tumor origin. 
These types include: 
- carcinomas: group of cancers originating from epithelial cells, including the most common 
cancers such as breast, colon, lung or prostate cancer, 
- sarcomas: neoplasm derived from connective tissue (e.g. bone, cartilage, fat), originating from 
mesenchymal cells outside the bone marrow, 
- lymphomas and leukemias: neoplasm arising from blood cells that leave the bone  marrow and 
mature in lymph nodes and blood. 
1.2.1 Breast cancer progression 
Breast cancer is the most common cancer among women and accounts for 25% of its all cases 60. 
In 2012, it resulted in 1.68 million cases and 522000 deaths 60. Although male breast cancer is 
more than 100 times less frequent, men have usually lower survival rates than women as a result 
of delayed diagnosis and more advanced disease at presentation 61. 
It is very hard to determine direct causes of breast cancer, as it is a very complex disease. There 
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are many factors which are associated with breast cancer risk, e.g. lack of childbearing or 
breastfeeding 62, higher endogenous estrogen levels 63, high fat diet, older age, smoking, viral 
infections, radiation, obesity and other environmental agents. 
Breast cancer classification is based on several grading systems, which contribute to patient’s 
prognosis as well as prediction of treatment response. Classification of the tumors can be assessed 
by means of its histological appearance. Breast cancer arises from epithelial parts of breast tissue, 
usually either from the inner lining of milk ducts or the lobules supplying ducts with milk and is 
referred to as ductal or lobular carcinoma, respectively. Additionally, breast carcinomas may be 
divided into carcinomas in situ, which are low-grade tumors that do not spread to the surrounding 
tissue, or invasive carcinomas, where cancer cells break through the wall of the milk duct and 
invade breast tissue.  
Progress in science during the recent years enabled categorizing tumors based on gene expression 
profiling with use of microarray analysis 64, 65. Owing to mRNA profiling, tumors can be 
identified as different subtypes, including luminal A, luminal B, basal- and normal-like 64-66. 
Majority of breast cancer subtypes are luminal, in which tumor cells resemble the inner epithelial 
cell lining of mammary ducts. Luminal A subtype is usually HER2- , ER+ and/or PR+ and due 
to its responsiveness to hormone therapy, has better prognosis, higher survival rates and lower 
recurrence when compared to other subtypes 67, 68. However, some luminal A tumors carry p53 
mutations, what contributes to their worse prognosis 68. Luminal B tumors tend to be ER+ and/or 
PR+ as well, but they have large number of actively dividing tumor cells. Moreover, their 
prognosis is worse, compared with luminal A subtype, due to different factors, such as bigger 
tumor size, lymph node positivity and p53 mutations 67-70. Basal-like tumors resemble 
myoepithelial cells lining basement membrane of the mammary duct 71 and usually are ER-, PR- 
and HER2-. They are more migratory, invasive and have a worse prognosis compared to luminal 
tumors 72-75. Normal-like tumors constitute only 6-10% of all breast cancers, are often small and 
tend to have a good prognosis 75. 
Some people have genetic mutations that make them more susceptible to breast cancer. However, 
only 5-10% of all breast cancer cases have a genetic background 76. The most frequent gene 
defects are found in the BRCA1 and BRCA2 genes. Women who carry mutations in those genes 
have even up to an 80% chance of getting breast cancer. Other significant mutations include: p53 
(Li-Fraumeni syndrome), PTEN (Cowden syndrome), and STK11 (Peutz–Jeghers syndrome), 
CHEK2, ATM, BRIP1, and PALB2.  
Death of breast cancer patients is caused mainly by spreading cancer to distant organs. During 
cancer progression, cells escape anti-proliferative control by acquiring several mutations in tumor 
suppressor genes, such as p53, phosphatase and tensin homolog Pten or retinoblastoma protein 
(RB) 77, and secrete their own stimulatory factors, what helps them to divide in an uncontrolled 
manner. Attained mutations and balance between activity of oncogenes and tumor suppressors 
enables the cells to acquire invasive phenotype.  
Breast cancer progression begins with attachment of tumor cells to the basement membrane, 
which is mediated by certain glycoproteins, like fibronectin and laminins 78. Attached tumor cells, 
as well as other cells from tumor microenvironment release enzymes, such as matrix 
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metalloproteinases, which disrupt basement membrane and degrade the matrix 79. Once tumor 
cells come in direct contact with remodeled stroma, their properties and behavior undergo 
modifications 80. They start to recruit inflammatory cells, such as leukocytes, macrophages and 
neutrophils to the tumor stroma, which as a result produce cytokines 81. Altogether, in order to 
invade, tumor cells lose cell-cell and cell-ECM interactions controlled by integrins and cadherins, 
and become more migratory owing to released chemokines and growth factors, and recruitment 
of stromal cells. Subsequently, invasive cancer cells migrate towards blood and lymphatic vessels 
and intravasate to the circulation 82. Their capability to secrete pro-angiogenic factors leads to 
promoting angiogenesis (e.g. VEGF-A) and lymphangiogenesis (e.g. VEGF-C) 83. As a 
consequence, new vessels produce chemokines and other stimulating factors for the tumor cells 
84. Since tumor blood vessels have abnormal structure and are usually not covered with pericytes 
and smooth muscle cells, what causes their leakage and high permeability, tumor cells are able to 
enter the circulation. Moreover, tumor cells can also intravasate to the lymphatic vessels, as they 
lack the tight inter-endothelial junctions typically seen in blood vessels, as well as the surrounding 
layers of pericytes, smooth muscle cells and basement membranes 85. Finally, breast cancer cells 
which passed the intravasation barrier, are able to form metastases at distant sites, such as lung, 
bone and liver 86. 
1.2.2 Colorectal cancer progression 
Colorectal cancer is one of the leading cancer-related deaths worldwide  Although survival rates 
of patients continue to increase with time, mainly as a result of improved diagnostics and 
treatment, 5-year survival remains below 60% in Europe 87. Major cause of mortality in 
colorectal cancer patients is liver metastasis, either present already at cancer diagnosis stage, or 
developing after primary tumor resection.  
Colonic epithelium consists of approximately ten million invaginations, called crypts. The base 
of the crypt contains dividing stem cells and multiplying daughter cells and is a starting point 
for the cell migration towards the epithelium surface, where the cells die and become replaced 
by continuously streaming new cells.  
Histopathologic changes appear as a consequence of both genetic and environmental factors. 
Main environmental factors involve pathogen invasion, toxins, polyamines, ROS (reactive 
oxygen species) production and stress. Somatic and inherited mutations affect multiple genes, 
e.g. APC (adenomatous polyposis coli), K-RAS, β-catenin, COX2  (cyclooxygenase-
2), SMAD4,  TGF-βR2 (transforming growth factor-beta Receptor-Type II), BAX  (Bcl2 
associated-X protein), MMPs (matrix metalloproteinases), E2F4  (E2F Transcription Factor-4), 
MMR (mismatch repair) genes and many others 88, 89. Genomic instability enables cells to 
acquire necessary mutations to turn into a cancer cell 90. 
Progression of majority of colorectal cancers involves multiple morphological stages. In the 
beginning, some of the crypts appear to accumulate cells at the surface, forming either 
hyperplastic or dysplastic tissue. As a result or excessive cell accumulation, polyps start to grow 
and protrude from epithelial surface. Dysplastic polyps, referred to as adenomas, become more 
dysplastic with time, while hyperplastic polyps become cancer mainly in a nonclassical manner. 
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The growth of adenomas is triggered by adverse conditions like bacterial or viral invasions, 
subsequently causing mutation in the APC (Adenomatous Polyposis Coli) regulatory 
pathway 91 usually affecting either APC or β-catenin. APC represses β-catenin, which reduces 
the tendency to abnormal tissue expansion by enhancing expression of proteins promoting cell 
division and affecting cell adhesion. As cells migrate from base crypts towards the epithelium 
surface, APC expression increases and inhibits β-catenin, what in turn promotes apoptosis at 
the surface and at the same time provides optimal balance in production from the crypt base. 
COX2 mutations are responsible for transformation of dysplastic epithelium (stage I) to early 
adenoma phase (stage II) and appear in the majority of human colorectal adenocarcinomas. 
Next stage in progression involves mutations in RAS genes, where the most common gene 
affected is K-RAS and less commonly H-RAS. K-RAS mutations, next to common mutations in 
DCC, MLH1 and MSH2 enable the transition from early to late adenoma (stage III). 
Additionally, late adenomas undergo other type of mutations, like aneuploidy, loss of 
heterozygosity or altered DNA methylation, to name a few 90. Finally, progression to tumor 
metastasis (stage IV), most commonly affecting liver, lungs, bone and brain, involves other 
genes, such as BAX, E2F4, MSH3, MSH6, TGF-βR2, BAX and MMPs, p53 and SMAD4. 
1.2.3 Metastasis 
Metastasis is a complicated process, during which cancer cells spread from the primary tumor to 
the distant organs in the body (Fig. 3).  
 
Fig. 3 Metastatic process. 
In order to survive and proliferate in a new tissue microenvironment, cancer cells acquire certain 
properties and undergo a series of metastatic events 92. This process is often referred to as 
metastatic cascade, which involves multiple steps and engagement of various signaling pathways 
93, 94. The most crucial events of the cascade are mobilization of cancer cells, followed by 
intravasation of the tumor vasculature and subsequently, extravasation and colonization at 
secondary sites.  
1.2.3.1 Routes of metastatic spread 
There are different routes, which tumor cells use in order to metastasize. The most typical one for 
sarcomas and some carcinomas (e.g. renal cell carcinoma) is hematogenous, in which tumor cells 
are transported within the blood circulation. For carcinomas, on the other hand, lymphatogenous 
spread is the most common and it allows tumor cells to reach lymph nodes and finally, other parts 
of the body. As lymphatics drain into systemic venous system, cancer cells can eventually enter 
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the bloodstream. Alternative route of metastasis occurs through seeding of body cavities, such as 
pleural, pericardial, peritoneal or subarachnoid cavities. For example, lung cancer can spread 
through the pleural cavity, while ovarian cancer might be transported transperitoneally to the liver 
surface. 
1.2.3.2 Mechanisms of metastasis development 
Currently, there are different theories explaining the mechanisms of development of distal 
hematogenous metastases. Namely, such metastases can result either from direct blood vessel 
intravasation at the primary site or originate from the tumor cells that have previously colonized 
local lymph nodes 92.  
1.2.3.2.1 Intravasation 
Intravasation initiates detachment of cancer cells from the primary tumor site and involves their 
invasion through the basal membrane into surrounding blood or lymphatic vessels 95. Cancer cells 
can use both active and passive approaches to penetrate the vasculature.  
Active intravasation assumes an active migration of tumor cells toward and into the closest blood 
vessel 96. At the beginning, cancer cells adhere to venular endothelial cells, and then to the 
subendothelial basement membrane proteins, such as type IV and V collagen and laminin. Finally, 
tumor cells adhere to connective tissue components, for example type I collagen, fibronectin and 
hyaluronan, what contributes to tumor cell invasion into subendothelial stroma as well as growth 
at the site of metastasis 97. Among the proteins contributing to intravasation is urokinase (uPA), 
an enzyme degrading extracellular matrix (ECM) elements and basement membrane. Moreover, 
uPA is responsible for activation of several growth factors and metalloproteinases (MMPs), 
which also degrade ECM, leading to tumor invasion and intravasation 98. Additionally, studies 
have shown that tumor-associated macrophages, which are a part of metastatic tumor 
microenvironment 99, 100, increase tumor cell migration and intravasation by secretion of 
chemokinetic and chemotactic factors 100, 101. These factors not only remodel ECM, but also 
promote angiogenesis and control collagen fibers formation. 
In passive intravasation, tumors spread through inactive shedding 96. It has been shown that large 
numbers of space-deprived tumor cells push against each other, causing stress which might 
compress the vessels and as a consequence, drive tumor cells into the vessels 102. Another study 
supporting passive intravasation demonstrated that primary tumor trauma or massage increases 
the amount of cancer cells entering the bloodstream 103. 
Migratory properties, which enable tumor cell intravasation, may be acquired during a process 
called epithelial-mesenchymal transition (EMT), which is characterized by loss of cell 
adhesion, repression of E-cadherin expression, as well as increased cell motility. Tumor cells, 
which undergo EMT may either intravasate as single cells or cooperate with non-EMT cells, 
helping them to complete the spontaneous metastasis process. However, even though both cell 
types persist in the circulation, only the ones with adhesive properties are able to attach to the 
vessel wall and extravasate into the secondary metastasis site 95. Mesenchymal phenotype of an 
EMT cell may be reverted by mesenchymal-epithelial transition (MET), which means that the 
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same cell is able to first enter into the vessel due to EMT and subsequently undergo MET, 
extravasate and continue metastatic process. 
1.2.3.2.2 Lymph nodes infiltration 
In the second hypothesis concerning metastasis formation, cancer cells initially invade lymph 
nodes and subsequently spread from lymph nodes to the blood vessels. This might be possible by 
tumor cell migration to the efferent lymphatics, followed by reaching vena cava, enabling further 
hematogenous dissemination. Although lymphatic intravasation is strongly associated with tumor 
lymphangiogenesis, mechanisms linking lymphangiogenesis with cancer metastasis are still 
under discussion. In one of the studies, PDGF-BB expression in murine fibrosarcoma cells 
induced tumor lymphangiogenesis, increasing number of lymph node metastases 104. In other 
studies, tumor cells have been shown to invade into lymphatics and form metastasis through the 
expression of chemokine receptors, such as CXCR4 and CCR7, corresponding to expression of 
respective ligands (CXCL12 and CCL21) in secondary metastatic sites 105. 
1.2.3.3 Circulating tumor cells 
Cells that have detached from the primary tumor and successfully enter the bloodstream are 
referred to as circulating tumor cells (CTCs). Their presence and behavior provide information 
on the biology of cancer and factors such as structure of vessels and metastatic potential of tumor. 
Breast cancer patients with higher levels of CTCs as compared with the group having lower CTCs 
levels, had a shorter median progression-free survival and shorter overall survival, what led to the 
conclusion that number of CTCs is an independent prognostic factor for patients survival at any 
time of breast cancer disease 106.  
The role of CTCs as a prognostic factor has been also demonstrated in castration-resistant prostate 
cancer patients 107, as well as metastatic breast and colon cancer patients 108, 109 with use of 
CellSearch system developed by Veridex, a method approved by Food and Drug Administration 
(FDA) for the detection of CTCs in whole blood. CellSearch technology is based on 
immunofluorescent labeling of epithelial cells (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 
19+) combined with automatic confocal microscopy. Despite its advantages, the method is 
expensive, not sensitive enough and detects only CTCs with epithelial phenotype. Since it is 
known that aberrant activation of EMT process occurs during tumor progression 110, CTCs can 
also exhibit mesenchymal phenotype 111. Thus, the dynamic changes between epithelial and 
mesenchymal phenotypes of CTCs have to be further investigated in order to understand the role 
of specific CTCs subsets in cancer metastasis. 
1.2.3.4 Direction of metastatic spread 
Occurrence of metastases is the one of the most intriguing, yet still not enough explored areas 
in cancer field. The distribution pattern of secondary growths in breast cancer has been 
originally proposed by Paget et al. 112, according to ‘seed and soil’ hypothesis. This hypothesis 
assumes that cancer cells, in order to metastasize, have to find a location with similar 
characteristics to their original microenvironment 113. Nevertheless, according to another 
theory, proposed by James Ewing, metastasis occurs only through anatomic and mechanical 
routes.  
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It is known that particular tumor types infiltrate certain organs but the detailed explanation of 
this phenomenon is still unknown. However, identification of genetic determinants of cancer 
metastasis 114 and CTCs’ infiltration into specific organs 115, 116 provided new insights into 
targeted cancer spread.  
Breast cancer metastasizes mainly to bone, lungs, regional lymph nodes, liver and brain. There 
are many various barriers that prevent CTCs to infiltrate specific organs, including basement 
membrane as a physical barrier, reactive oxygen species, low pH and hypoxia as chemical 
barriers and many biological factors, such as immune response or cytokines 117. Moreover, 
organ-specific metastasis is largely influenced by expression of receptors on tumor cells, 
regulation by adhesion molecules and chemoattractants, as well as certain physical features of 
colonized organs. For example, bone marrow, as one of most common secondary sites of 
metastasis, is built of capillaries, referred to as sinusoids, which are composed of epithelial cells 
cross-linked with cell gates allowing for penetration of hematopoietic cells 118. In a similar 
manner, the structure of liver capillaries facilitates CTCs’ extravasation 119. In lung vasculature, 
which is another frequent metastasis target site, a metadherin binding site has been found, a 
protein that is overexpressed in metastatic breast cancer 120. Compared to the other metastatic 
sites, brain is the most difficult organ to colonize, as cancer cells have to pass the blood-brain 
barrier in order to create micrometastases. However, the homing or adhesion mechanisms, 
facilitating brain metastasis still remain unclear. 
1.2.4 Cancer immunology 
Cancer immunology is an area in medicine and research, focused on the interplay between 
cancer and immunological system. There are two main concepts which are closely related to 
cancer immunology – immunosurveillance and immunoediting. The idea that the immune 
system could defend the host from neoplastic disease was originally proposed by Ehrlich 121 in 
1909, but officially cancer immunosurveillance term was introduced nearly 50 years later by 
Burnet and Thomas, who identified lymphocytes as main guardians in immune sytem that 
recognize and destroy quickly arising transformed cells 122. Described process aims at host 
protection, inhibition of cancer development and maintenance of cell homeostasis 123. 
Immunosurveillance is included into more basic concept of immunoediting, which assumes that 
immune system is a major host defender against cancer 123. Immunoediting involves three 
consecutive stages: elimination, equilibrium and escape 124.  
Elimination stage consists of a series of events, initiated when the innate immune system cells 
recognizes the presence of a growing tumor, due to local tissue disruption, caused by stromal 
remodeling process. This remodeling process, resulting from angiogenesis and tissue-invasive 
growth, induces production of inflammatory molecules, which together with tumor-produced 
chemokines 125 recruit the innate immune system cells to the tumor site. Among recruited cells 
there are natural killers T (NKT) cells, natural killer (NK) cells, macrophages and dendritic 
cells, which use different means of ligand recognition of the tumor cells. This process leads to 
the production of IFN- γ, which is a key step in progression of antitumoral response. 
Subsequently, IFN- γ induces local production of chemokines, which recruit more cells of the 
innate immune system, and lead to tumor death by activating several IFN-γ-mediated processes, 
having an angiostatic 126, proapoptotic 127 and antiproliferative 128 effects on the tumor. 
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Additionally, IFN- γ-activated macrophages and NK cells can destroy tumor cells by either 
perforin 129, or TRAIL-dependent 130 mechanisms. Consequently, tumor antigens become 
accessible and tumor-specific adaptive immune system becomes involved. Immature dendritic 
cells that have been attracted to the tumor area are activated via cytokines released by innate 
immune response or interaction with recruited NK cells 131. After activation, dendritic cells 
acquire tumor antigens and migrate to the draining lymph nodes 132, where they trigger 
differentiation of naïve tumor-specific Th1 cells. Th1 cells are a subgroup of CD4+ T-cells, 
which facilitate development of tumor-specific CD8+ cytotoxic T cells 133. Finally, CD4+ and 
CD8+ T-cells home to the tumor site and kill the antigen-bearing tumor cells. 
Cancer cells that have not been eradicated during the previous phase enter equilibrium stage. In 
this stage, IFN- γ and lymphocytes exert selection pressure on remaining tumor cells, which 
lack genetic stability. Even though many tumor cells are destroyed during this process, new 
tumor cells clones with decreased immunogenicity arise.  
Selected tumor clones enter escape stage and are able to expand ad form clinically detectable 
tumors. Cancer cells use different strategies to avoid host’s antitumor immune response, such 
as release of immunosuppressive cytokines (IL-10, TGF-β) or involvement of regulatory T cells 
124. Tumor escape might also be a result of changes occurring directly at the tumor level. These 
changes might affect tumor recognition by effector cells, for example by losing MHC 
components 134, losing tumor-specific antigen expression, downregulation of NKG2D 135 or 
developing insensitivity to IFN- γ 136. Other possible alterations allow the tumors to escape 
immune responses, for example by developing apoptosis resistance 137 or faulty death-receptor 
signaling 138. Identification of more escape mechanisms might provide essential information on 
interactions between the tumor and immune system. 
Cancer immunology research is focused on discovering new cancer immunotherapies, such as 
vaccines or antibody therapies. In order to achieve this, it is necessary to identify the targets for 
immune recognition in cancer 122. For example, presence of lymphocytic infiltration in the 
tumor have been correlated with improved clinical outcomes of colorectal cancer patients 139. 
1.2.5 C/EBPβ 
C/EBPβ is a protein belonging to C/EBP (CCAT-enhancer-binding protein) family, which 
regulates expression of several genes controlling cell proliferation, differentiation, inflammation 
and metabolism. C/EBP family consists of six transcription factors called C/EBPα to C/EBPζ and 
is characterized by presence of basic leucine zipper (bZIP) domain at the C-terminus, which is 
required for dimerization and DNA binding.  
C/EBPβ can form heterodimers with other members of the C/EBP family, such as C/EBPα, 
C/EBPγ and C/EBPδ, as well as with other transcription factors like CREB1 140 or Sp1 141. It is 
also capable of binding as a homodimer to certain DNA regulatory regions and hence, controlling 
the expression of numerous target genes. Among them, there are genes playing a role in the 
nervous system, such as PPT-A (preprotachykinin) gene 142 and the choline acetyltransferase gene 
143. 
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The intronless C/EBPβ gene encodes three different protein isoforms: LAP1, LAP2 (liver-
enriched activator proteins) and LIP (liver-enriched inhibitor protein), expressed depending on 
differential use of specific in-frame translation sites 144, 145. While LAP1 and LAP2 are 
transcriptional activators, LIP usually plays the role of their inhibitor. Nevertheless, functions of 
all C/EBPβ isoforms are still under investigation and largely dependent on the cellular context. 
Alternative C/EBPβ isoform production is tightly regulated by the mammalian target of 
rapamycin (mTOR) pathway, where mTOR activation stimulates LIP expression and mTOR 
inhibition enhances LAP production 146. Additionally, the truncated LIP isoform may beformed 
by partial proteolysis of longer C/EBPβ isoforms 147. While all the isoforms contain C-terminal 
bZIP domain, LAP1 and LAP2 harbor also N-terminal transactivation and chromatin remodeling 
domains. The ratio of C/EBPβ isoforms is thought to determine cell fate 148, 149.  
As a transcription factor, C/EBPβ interacts with several target genes and is required for a variety 
of biological processes, such as adipogenesis (126-129), embryogenesis 150, granulopoiesis 151, 
muscle repair (116-118) and osteoporosis (121-125). Moreover, it is involved in controlling cell 
growth, autophagy and antibacterial defense (130-131), as well as in regulating insulin level and 
insulin receptors expression (132-134). Finally, C/EBPβ regulates multiple genes responsible for 
immune and inflammatory responses. It has been shown to bind to cytokine coding genes such as 
IL-6 152, IL-4 153, IL-5 154 and TNFα 155 and be responsible for activation and terminal 
differentiation of macrophages, an important immune cell subtype (75). As C/EBPβ expression 
plays a role in astrocyte inflammatory response, its expression is changed in various neurological 
disorders including Alzheimer’s disease 156, Parkinson’s disease 157 and HIV-1-associated 
dementia 158. 
In this thesis, particular emphasis is put on the role of C/EBPβ in breast cancer. Its gene is usually 
not mutated in this form of cancer. A few rare mutations that have been found are doubted to 
contribute to epithelial tumors 159. Nevertheless, C/EBPβ might be amplified in a small subgroup 
of breast neoplasia, described as lobular carcinoma in situ 160. Elevated levels of C/EBPβ mRNA 
are associated with metastatic breast cancer 161, higher tumor grade 162, 163 and overall worse 
prognosis 161.  
1.2.5.1 Mammary gland development 
Both LAP1 and LAP2 are expressed in non-malignant, human mammary epithelial cells 164, as 
well as in breast tumors 165, 166. LAP1 is mainly expressed in normal mammary cells, whereas 
LAP2 is found only in dividing cells, both normal and neoplastic 167.  
Studies in vitro as well as in vivo have showed significant contribution of C/EBPβ isoforms to the 
mammary gland development and breast cancer. For instance, in vitro studies have shown that 
LIP overexpression in mouse mammary epithelial cells 168 or fibroblasts 169 causes lack of contact 
inhibition, increased proliferation and foci formation. Additionally, transgenic mice with 
overexpression of LIP in the mammary gland develop alveolar hyperplasia, high grade mammary 
intraepithelial neoplasias as well as invasive and noninvasive carcinomas 168.  
Other studies, using C/EBPβ-/- mice, revealed that C/EBPβ is necessary for ductal 
morphogenesis, epithelial cell proliferation and functional differentiation in the murine mammary 
gland 170, 171. However, mice with abolished LAP2 expression displayed no abnormalities in 
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mammary gland development 172, what suggests that expression of this isoform is not crucial in 
this process and that LAP1 and LIP might compensate for the loss of LAP2.  
1.2.5.2 Cell survival and apoptosis 
The role C/EBPβ in cancer might be also explained by its ability to regulate cell survival and 
apoptosis. For example, C/EBPβ is essential for oncogenic transformation of macrophages and 
controls expression of insulin-like growth factor I (IGF-I), which is an important prosurvival 
factor 173. C/EBPβ is also critical in survival of hepatic stellate cells bearing DNA damage due to 
CCL4-induced free-radical formation 
174. Additionally, C/EBPβ promotes cell survival by 
repression of p53 expression and altering its function in keratinocytes in response to DNA damage 
175 and carcinogen-induced stress 176. 
Apoptosis is a process of programmed cell death controlled by various factors. It has been 
demonstrated that MAPK-RSK-C/EBPβ signaling is crucial for liver fibrosis and modulates 
stellate cell survival through caspase 8-associated protein FLIPL 177. In addition, studies on 
C/EBPβ-null mice display lowered apoptotic liver injury and reduced activation of caspase-3 178. 
Reduced levels of C/EBPβ may also lead to resistance to DMBA-induced skin tumorigenesis by 
increased apoptosis 179. 
1.2.5.3 Cell growth and senescence 
C/EBPβ is often involved in proliferation, for example in liver, where this process is promoted 
via interaction of C/EBPβ with HDAC1 180. On the other hand, in vitro studies have shown that 
forced expression of LAP2 may lead to growth arrest in normal cells, such as keratinocytes 181 or 
fibroblasts 182, as well as in cancer cells like hepatocarcinoma cells 183. It has also been 
demonstrated that oncogene-induced senescence involves C/EBPβ-dependent expression of 
certain chemokines, such as CXCR2 184 and activation of the inflammatory networks 185. In 
addition to that, C/EBPβ is required for Ras-induced senescence by acting downstream or 
independently of p19ARF/p53 186. 
Overexpression of LAP2 in MCF10A cells leads to foci formation, anchorage independence, 
epithelial-mesenchymal transition and acquirement of invasive phenotype 187. Nevertheless, 
LAP2 overexpression in LIP-rich breast cancer cells causes decreased proliferation and 
senescence 166. Hence, the ratio of C/EBPβ isoforms is essential for normal cell growth and 
development and their altered expression may lead to aggressive forms of breast cancer. For 
example, a high LIP: LAP ratio in human breast carcinomas correlates with more aggressive 
phenotype and poor prognosis 165, 188, 189. 
1.2.5.4 Epithelial-mesenchymal transition (EMT) 
Epithelial-mesenchymal transition (EMT) is a reversible process allowing epithelial cells to lose 
their cell polarity and cell-cell adhesion, and to achieve migratory and invasive abilities to trans-
differentiate into mesenchymal-like cells 190, 191. It has been shown that cycles of both EMT and 
MET (mesenchymal-epithelial transition) are required for embryo formation 192-194. Nevertheless, 
EMT occurs also in wound healing, organ fibrosis, as well as cancer progression 192, 195.  
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Epithelial cells are in close contact to each other owing to tight junctions, gap junctions and 
adherens junctions, have apico-basal polarity high E-cadherin expression, polarized actin 
cytoskeleton and rest on a basal lamina. Conversely, mesenchymal stem cells communicate with 
each other only by focal points 196, lack polarization and display spindle-shaped morphology, 
expressing factors such as N-cadherin, fibronectin and vimentin. Therefore, EMT involves 
prominent changes on a morphological, as well as phenotypical level. 
The crucial event in EMT involves loss of E-cadherin, which is controlled by different 
transcription factors. While Snail1, Snail2 (Slug), ZEB1, ZEB2, E47 and KLF8 repress E-
cadherin transcription, other factors like Twist, Goosecoid, TCF4 or FOXC2 repress E-cadherin 
expression in an indirect manner. In addition, EMT can be induced by several growth factors in 
cancer, including Notch 197, epidermal growth factor (EGF) 198, hepatic growth factor (HGF) 199, 
Wnt factors 200, and transforming growth factor β (TGF-β) 201, which is considered to be a major 
EMT inducer in cancer. 
Studies on the invasive cancer front showed cancer cells expressing both epithelial and 
mesenchymal markers, spreading from tumor mass into the adjacent stroma. Different cancer cell 
phenotypes and EMT were described in multiple cancer types, including breast 202, colon 203, 
cervical 204, thyroid 205, ovarian 206 and oral squamous cell carcinoma 207.  Moreover, EMT have 
been shown to promote metastasis 208 and associated with metaplastic 209 and basal-like breast 
carcinoma 210, as well as other higher tumor grades, what suggests that EMT might aggrevate 
clinical outcome 211. Additionally, some of EMT markers, like Snail and Twist, correlate correlate 
with relapse of breast 212, bladder 213 and ovarian cancer 214.  
1.2.5.5 Associations with breast cancer treatment 
Interplay between epithelium and stroma is crucial for aromatase expression and estrogen 
production in breast cancer tissue 215. Upregulated aromatase expression in breast fibroblasts 
increases production of estradiol (E2), activating several carcinogenic genes via estrogen 
receptor-α (ERα) in malignant epithelial cells. In order to avoid this effect, aromatase inhibitors 
(AIs) are used in the clinics, being nowadays the most effective hormonal treatment for estrogen-
responsive breast cancer 216. As aromatase expression is controlled by different signaling 
pathways, it is highly desirable to target these pathways and inhibit estrogen production in 
selected tissues. C/EBPβ has been shown to regulate aromatase expression in human fibroblasts 
in the breast adipose tissue, and therefore, it might indirectly contribute to breast cancer 
progression 217. 
Another example of indirect role of C/EBPβ in breast cancer is its ability to activate the genes 
conferring multidrug resistance to the cells, such as ABCC2 218 or ABCB1 219-221. These genes 
encode proteins belonging to ATP-binding cassette transporters (ABC-transporters) family, 
which are frequently overexpressed in breast cancers. Moreover, elevated levels of ABC 
transporters like ABCB1 have been correlated with chemotherapeutic outcomes 222, what 
suggests that C/EBPβ, by activation of ABCB1, plays a secondary role in chemoresistance in 
breast cancer. 
Receptor tyrosine kinase signaling has a significant function in development of various types of 
cancer. Mammary tumorigenesis in particular is influenced by epidermal growth factor (EGF) 
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receptor and fibroblast growth factor (FGF) receptor families, which are strongly associated with 
C/EBPβ 223. For example, it has been demonstrated that ErbB1–EGFR signaling regulates the 
differential translation of the LAP and LIP isoforms, causing increased LIP expression 164, 224 and 
subsequently, higher LIP:LAP ratio, which contributes to promoting proliferation and a more 
aggressive disease phenotype. In addition, C/EBPβ is involved in EGFR regulation of FGF 
activity and FGFR2 expression in breast epithelial cells 225, 226.  
C/EBPβ has been also proven to negatively regulate one of the microRNAs that is often 
downregulated in tumors, miR-145. Both isoforms of C/EBPβ take part in miR-145 regulatory 
system involving Akt pathway, what might explain the downregulation of miR-145 in cancer 
cells 227. 
In summary, C/EBPβ is involved in many aspects of breast cancer development and progression 
by affecting several biological pathways. However, additional in vitro, as well as in vivo studies 
are needed to unravel the specific mechanisms explaining C/EBPβ function in breast cancer.  
1.2.6 MSCs and chemokines in cancer 
Mesenchymal stem cells as a part of tumor microenvironment are important factor affecting 
tumor development 228. However, their role in this process still remains controversial. Dependent 
on the biological context and multiple factors, they might either promote tumor progression or 
act as tumor suppressors. Using different sources of tissue, individual donor variability and timing 
of MSCs injection contributes to discrepancies between the studies. Furthermore, expression of 
certain receptors (e.g. toll-like receptor, TLR) fluctuates in different time points during MSCs 
treatment 229, what may also affect MSCs influence on cancer progression. Although it is clear 
that MSCs administered systemically migrate towards tumors 230, 231, their precise role in cancer 
development is still under discussion. 
MSCs have been shown to have therapeutic potential in targeting several cancer types, including 
breast cancer 232, brain tumors 233, liver cancer 234, 235, leukemia 236, pancreatic cancer 237 and 
sarcoma 238 in various animal models. Some reports indicate that MSCs suppress tumor 
development by cell fusion 239 or through p38 mitogen-activated protein kinase (MAPK) 240. 
Conversely, other studies revealed that MSCs support tumor growth in colon cancer 241, 
lymphoma 242 and melanoma 243. However, this effect was explained by Klopp at al., who 
suggested that increased MSCs proliferation in the tumor leads to augmented tumor mass 244. 
Moreover, MSCs in tumor stroma were shown to promote breast cancer metastasis by immune 
modulation 245 and regulate EMT and tumor progression in pancreatic cancer cells 246. 
Interestingly, MSCs have also been reported to be a source of cancer-associated fibroblasts 
(CAFs) which are major contributors to cancer progression 247. 
There are numerous reports describing the function of MSCs in colon cancer progression. 
Specifically, MSCs modulate the tumorigenicity of human colon cancer cells via interleukin-6 
(IL-6) 248 and promote formation of murine colorectal tumors 249. Moreover, MSCs enhance 
growth and metastasis of colon cancer by promoting angiogenesis, migration, and invasion and 
by repressing tumor cell apoptosis 241. 
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Homing of MSCs to the tumor involves action of multiple factors, controlling cell migration 
towards inflammation, such as growth factors, chemokines and cytokines. One of the chemokines 
engaged in this process is stromal cell derived factor 1α (SDF1α), which secreted from cancer 
cells enhances MSCs migration towards the tumor in Helicobacter-mediated gastric cancer model 
250. Another example is chemokine (C-C motif) ligand 5 (CCL5), which augments cancer cell 
migration and invasion, and thereby, contributes to MSC-induced breast cancer metastasis 245.  
In addition to chemokines, chemokine receptors affect tumor progression as well. Namely, CCR1 
was reported to mediate accumulation of myeloid cells in the liver microenvironment, enhancing 
mouse colon cancer metastasis 251, 252. Furthermore, CCR1 promotes liver metastasis by 
regulating angiogenesis 253. Another chemokine receptor, CCR2, has been found to be 
upregulated in MSCs subject to irradiated tumor cells and its inhibition resulted in diminished 
MSC migration in vitro 254. 
1.2.6.1 CCL7 in cancer 
Chemokine (C-C motif) ligand 7 (CCL7), known also as monocyte-specific chemokine 3 
(MCP-3), is a chemokine which attracts monocytes and regulates function of macrophages. 
Identified originally from osteosarcoma supernatant 255, CCL7 expression was observed in 
several cell types, including monocytes, fibroblasts, platelets, colon epithelial cells and some 
tumor cell lines 256-258. As CCL7 interacts with multiple leukocyte receptors, it is capable of 
activating monocytes and granulocytes 259. In support of this, CCL7 has been also shown to 
drive TNFα-dependent Th1/Th17-mediated inflammation in psoriasis. Finally, locally 
overexpressed MCP-3 was shown to recruit MSCs to injured tissue and improve cardiac 
remodeling 260. 
The topic of CCL7 role in tumor progression appeared in the literature already over a decade 
ago. One of the first described studies indicated that CCL7 gene transfer to mastocytoma cells 
resulted in reduced tumorigenicity, increased neutrophil recruitment to the tumor and enhanced 
dendritic cell infiltration in peritumoral tissue 261. Another study showed that CCL7 gene 
transfection to colorectal cancer cell line resulted in tumor growth retardation and metastasis 
inhibition 262. On the other hand, several other research groups revealed that CCL7 expression 
can be associated with enhanced invasive and metastatic properties. Namely, CCL7 was 
reported upregulated in cancer-associated fibroblasts (CAFs) cultured with oral squamous cell 
carcinoma (OSCC) cells and promoted tumor migration and invasion in vitro 263. Subsequently, 
CCL7 overexpression was associated with lymph node metastasis and poor prognosis in gastric 
cancer 264. Moreover, brain cancer metastases were shown to carry higher expression of CCL7 
compared to primary tumors of renal cell cancer (RCC) 265. Finally, recent studies confirmed 
the role of COX2-MMP1/CCL7 axis in brain cancer metastasis 266. 
Interestingly enough, CCL7 receptors CCR1, CCR2 and CCR3 were found overexpressed in 
liver metastatic tumor tissues of the patients and had upregulated expression levels in hepatic 
recurrences, when compared with primary tumors 267. It was also the first clinical report 
presenting CCL7 as a novel target in liver metastasis of colorectal cancer. Nevertheless, the 
mechanisms underlying CCL7 importance in colorectal metastasis have not been yet explained.  
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2 AIMS OF THE STUDIES 
 
- quantitative and functional characteristics of MSCs and pericytes in the vascular wall 
- characterisation of receptors for chemokines, cytokines and growth factors present on 
MSCs and pericytes and determining how chemokines and cytokines modulate 
migration and differentiation of mural cells 
- studying the relationship between EMT and C/EBPβ expression in breast cancer 
- analyzing function of C/EBPβ in formation of mestastasis and its effect on vascular 
morphology 
- determination if C/EBPβ can be one of the prognostic markers in diagnostics of 
metastatic breast cancer patients  
- analyzing crosstalk between MSCs and colon cancer  
- discovering the role of CCL7 in colon cancer progression  
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3 RESULTS AND DISCUSSION 
3.1 STUDY I 
Intimal hyperplasia is not only a healing response, but also main cause of vessel narrowing 
after injury. This process involves migration of vascular progenitor cells, what might lead to 
transplant arteriosclerosis. The goal of this study was to analyze the role of MSCs in intimal 
hyperplasia and to determine factors affecting their recruitment. Rejection of transplanted 
organs is often associated with inflammatory response and secretion of factors activating 
cells in surrounding tissues. Therefore, in order to find out how allografts influence the 
adjacent vessel tissues, we transplanted a fragment of rat isogenic (from F344 rats) or 
allogenic (from LEW rats) aortic graft into the abdominal aorta of F344 rats and collected 
samples of tissues at different timepoints.  
Immunohistohemical analysis of 2-week-old allografts showed decreasing α-smooth muscle 
actin expression in medial layer and migration of α-smooth muscle actin positive cells to 
neointima. Adjacent vessels displayed similar, but less extensive structural alterations. 
Interestingly, electron microscopy performed at 1 to 2 weeks after transplantation, showed 
architectural changes in SMCs in the inner part of the media and progressing allograft de-
endothelization. While most of SMCs had a contractile phenotype with well-organized 
myofilaments, some of them exhibited synthetic phenotype characterized by increased Golgi 
system and ER size. Once again, similar but less prominent changes were observed in the 
adjacent vessels.  
Staining for α-smooth muscle actin at week 4 showed less SMCs in the media, coinciding 
with increasing fibrosis and inflammation. In the neointima, we observed more SMCs and 
inflammatory cells. 
Remodeling process continued until week 8, when inflammation in the allograft had already 
started decreasing. Medial layer developed fibrosis with enhanced ECM and allograft intima 
grew in size, mainly consisting of contractile SMCs and leukocytes. On the contrary, 
adventitia did not show structural abnormalities. The study revealed that adjacent tissue 
underwent structural alterations similar to the ones in allograft, but less prominent. Namely, 
in adjacent tissue, a thin layer of intima, as well as SMCs of both contractile and synthetic 
phenotypes in the media were observed. 
In order to assess if neointimal cells may be derived from other vessel layers in the allograft 
or adjacent vessels, we performed transplantation of female-to-male F344 isotypic insert into 
a female LEW rat. Real time PCR analysis for SRY gene of aortic allograft intimal lesion 
revealed that cells derived from adjacent vessel were detected at low levels in the allograft, 
only at late timepoints (12 weeks after transplantation) and in 25% of rats. Therefore, 
possibility of adjacent vessel being a source of migratory cells contributing to formation of 
allograft intima was excluded. 
Subsequently, another experiment was performed to determine if adventitia could provide 
the cells incorporated into intima. Specifically, orange cell tracer labeled male LEW 
adventitia was transplanted into F344 female allografts that had previously been transplanted 
into LEW rats. In this setting, the isogenic labeled adventitia was not subject to allogenic 
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inflammation. 14 days after transplantation, we observed extensive migration of labeled cells 
into the intima, where nearly 80% of intimal cells originated from adventitia. 
To determine different subpopulations of adventitial progenitor cells migrating into the 
intima, we used flow cytometry analysis, which identified CD90+, CD44+ and sca-1+ cells 
as predominant cell phenotype in the adventitia. Immunohistochemical analysis and confocal 
microscopy revealed equal distribution of described cell populations in the adventitia and 
only a few CD90+, CD44+ and sca-1+ cells in the media. Double stainings for the previously 
used progenitor cell markers were performed and indicated that nearly 14% of adventitial 
cells were double-positive for CD90 and CD44, while only 3-6% of cells were double-
positive for sca-1 and CD90 or CD44. 
Next, RNA microarray using allografts and adjacent vessel 2 and 8 weeks after 
transplantation was used as a screening method for essential factors for the recruitment of 
adventitia-derived cells to the intima. Increased expression of chemokines such as MCP1-1, 
RANTES, SDF-1 and interferon-inducible protein-10, as well as their receptors like CCR2, 
CCR5, CXCR3 and CXCR4, was found and confirmed by real time PCR. Additionally, PCR 
assays performed on nontransplanted aortas confirmed high levels of expression of 
mentioned chemokine receptors in adventitial cells. 
Afterwards, migration assays on rat adventitial cells were performed in response to MCP-1, 
RANTES, SDF-1 and interferon-inducible protein-10, which identified MCP-1 as the most 
potent chemoattractant. Furthermore, double stainings for CCR2 (MCP-1 receptor) and 
progenitor cell markers used for flow cytometry analysis confirmed expression of  CCR2 on 
CD90+, CD44+, sca-1+ cells, and  to smaller extent also on NG2+ cells.  
We followed our study using injury model as a way to determine if MCP-1 contributes to 
formation of intimal hyperplasia in a nontransplant model. Namely, arteries derived from 
C57BL/6 and MCP-1 knockout mice were mechanically injured and followed by 
transplantation of the labeled adventitia from C57BL/6 and CCR2 knockout mice. Almost 
half of the adventitial cells migrated to the intima and formed intimal lesion. Moreover, both 
transplantation to MCP-1 knockout mice and transplantation from CCR2 knockout mice 
hindered migration of adventitial cells by approximately 25%. 
Fluorescent immunohistochemical analysis for cells coexpressing CCR2 and CD90, CD44 
and sca-1 demonstrated presence of double-positive cells mainly in the adventitia and in the 
outer area of the media, what provided further proof of presence of MSCs in the vessels and 
their role in intimal hyperplasia.  
Subsequently, we showed that most of the MSCs derived from adventitia were able to 
differentiate into SMCs. Specifically, we sorted CD90+, CD44+, sca-1+ and NG2+ cells 
using flow cytometry, cultured them with PDGF-BB to induce SMC differentiation and 
stained them for α-smooth muscle actin and myosin. 
Finally, a fusion assay was performed between SMCs and adventitial cells by means of 
creLOX system in order to exclude the probability that adventitia-derived intimal SMCs are 
adventitial progenitor cells that have fused with SMCs. As a result, no fusion was noticed 
between adventitial cells and SMCs, even under forced conditions. 
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This study identified mesenchymal stem cells of adventitial origin as a cellular source 
contributing to intimal hyperplasia. Furthermore, it recognized MCP-1 as a potent chemokine 
involved in recruitment of adventitial progenitor cells to intimal lesions. 
3.2 STUDY II 
Cancer progression involves multiple factors, one of which is TGFβ. During this process, TGFβ 
role switches from growth inhibitor at early stage to a major inducer of EMT, invasion and 
metastasis in later stage. C/EBPβ, an essential factor regulating mammary gland development, 
has recently been shown to be deregulated in breast cancer 223. Additionally, studies published 
by Bundy et al. suggested that C/EBPβ might be involved in the TGF-β response towards both 
growth inhibition and EMT 187. Therefore, we decided to determine if loss of C/EBPβ has a 
preventive role against TGF-β- induced EMT in breast cancer. 
In order to examine the relationship between EMT and C/EBPβ expression in breast cancer 
cells, immunofluorescent staining followed by confocal microscopy analysis of samples of 
human breast carcinoma was performed. Specifically, C/EBPβ was stained in combination with 
E-cadherin, which is an EMT marker, commonly lost in invasive cancer. In samples of well-
differentiated DCIS, we observed prominent E-cadherin expression at cell-cell junctions and 
nuclear expression of C/EBPβ in breast cancer cells. 
In case of invasive ductal breast carcinomas, previously classified according to their estrogen, 
progesterone and HER2 receptor status, we found decreased E-cadherin expression in areas of 
triple-negative tumors. Moreover, these tumors expressed lower levels of E-cadherin compared 
with ER+, PR+ and HER2+ tumors and with HER2+ tumors. Nuclear C/EBPβ staining was 
diminished in triple-negative tumors and linear regression analysis revealed significant 
correlation between expression of E-cadherin and C/EBPβ in all analyzed IDC samples. 
Further examinations indicated to decreased C/EBPβ expression in E-cadherin-negative areas 
compared with E-cadherin-positive areas of the triple-negative tumors. 
In order to analyze C/EBPβ expression during breast cancer progression, we used transgenic 
mouse model overexpressing the polyoma virus middle T antigen under mouse mammary 
tumor virus promoter (MMTV-PyMT mice). Fluorescent double stainings of tumors derived 
from 10- and 14- week old MMTV-PyMT mice showed prominent loss of C/EBPβ expression 
in E-cadherin-negative areas compared with E-cadherin-positive areas of adenocarcinomas. 
To study if C/EBPβ is regulated during EMT, we employed commonly used model of TGF-
β1-induced EMT in mouse mammary gland epithelial cells (NMuMG). NMuMG cells, after 
48h treatment with TGF-β1, had not only decreased nuclear expression of C/EBPβ, but also 
showed typical signs of EMT, such as: exhibited elongated phenotype, lost expression of E-
cadherin and upregulated expression of vimentin. Additionally, Western blot analyses 
confirmed EMT phenotype of TGF-β1-treated NMuMG cells, showing decreased levels of the 
junction proteins E-cadherin, CAR, occludin and claudin-3, and enhanced levels of N-cadherin 
and vimentin, compared with untreated cells. All isoforms of C/EBPβ (LAP1, LAP2 and LAP) 
were decreased in examined cells and no changes in LIP/LAP ratio were observed. 
Furthermore, loss of C/EBPβ was shown to be specifically associated with EMT. Namely, 
EpH4 cells, which are resistant to TGF-β1-induced EMT were also treated with TGF-β1. As a 
result, neither morphological signs of EMT, nor changes in the expression of junction proteins 
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or mesenchymal phenotype proteins, such as N-cadherin or vimentin, were revealed. 
Additionally, TGF-β1 treatment caused activation of Smad3, but did not affect C/EBPβ levels.  
qPCR analyses showed that TGF-β1 treatment in NMUMG cells reduced mRNA level of E-
cadherin (Cdh1) by 60%, CAR (Cxadr) by 40% and C/EBPβ (Cebpb) only by 20%, what 
suggested possible involvement of posttranscriptional mechanisms in repression of C/EBPβ 
during TGF-β1-induced EMT. In order to verify if microRNA-155 (miR-155), a well-
recognized oncomiR in breast cancer 268, which targets Cebpb in macrophages and B cells  269, 
270, takes part in repressing C/EBPβ in TGF-β1-dependent EMT, NMuMG cells were treated 
with miR-155 inhibitor before TGF-β1 treatment. Inhibitor increased C/EBPβ expression at 
baseline and decreased its repression during EMT, what was confirmed by 
immunofluorescence analysis. Interestingly, additional inhibitor’s effect of 20% rescue of the 
repression of E-cadherin was confirmed only by qPCR, but not by immunofluorescence or 
immunoblotting. On the other hand, using miR-155 mimic instead of miR-155 inhibitor caused 
diminished levels of C/EBPβ at baseline, and further repression after TGF-β1 exposure. Further 
qPCR comparisons between the cells indicated that miR-155 levels were approximately 4.5 
fold higher in NMuMG cells compared with EpH4 cells at baseline, and even more increased 
in NMuMG cells upon TGF-β1 treatment, as shown in previous studies 271. Moreover, all three 
isoforms of C/EBPβ had higher expression in EpH4 cells compared with NMuMG cells. Loss 
of C/EBPβ during TGF-β1-induced EMT was inhibited by both siRNA against Smad3 and 
commercially available inhibitor, what proved that repression of C/EBPβ was mediated 
through the canonical TGF-β/Smad3 pathway. 
To determine whether miR-155-dependent loss of C/EBPβ might sensitize cells to TGF-β1-
induced EMT, we performed loss- and gain-of-function studies for C/EBPβ. Lentivirus-
mediated knockdown of C/EBPβ through overexpression of small hairpin RNA (shRNA, in 
NMuMG cells led to decreased expression of E-cadherin and CAR at baseline, as well as 
potentiated EMT induction after exposure to TGF-β1, demonstrated by further decrease of 
expression of E-cadherin and CAR and increase of expression of vimentin compared with cells 
expressing control shRNA. Conversely, transient overexpression of LAP2 in NMuMG cells 
caused increased mRNA levels of Cdh1 and Cxadr at baseline and diminished repression of 
those genes after treatment with TGF-β1.  
Subsequently, to assess if C/EBPβ re-expresssion would suffice to revert cells from a more 
established EMT phenotype, we used long-term EMT induction in NMuMG cells, known to 
cause prominent EMT and evasion of cytostatic effects of TGF-β1. NMuMG, treated for 14 
days with with TGF-β1 developed profound EMT phenotype with low expresion of E-
cadherin, CAR and C/EBPβ. LAP2 overexpression in long-term treated NMuMG cells led to 
increased expression of E-cadherin and CAR, decreased expression of vimentin, but not to 
EMT phenotype reversion as observed morphologically. Since overexpression of LAP2 did 
not change expression of Zeb1, Snail, Slug and Twist, we assessed that induction of E-
cadherin and CAR was not dependent on expression of those EMT factors. As already shown 
in previous studies, long-term treated NMuMG cells evaded growth inhibitory effect of TGF-
β1 and proliferated in a similar way to untreated cells. Additionally, LAP2 overexpression 
sufficed to restore the growth inhibitory effect of TGF-β1 in studied cells. 
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To study the effect of C/EBPβ expression on invasion, we performed chemoinvasion assays 
on NMuMG cells subject to TGF-β1. NMuMG cells expressing Cebpb shRNA were 
60% more invasive than cells expressing control shRNA, while NMuMG cells 
overexpressing LAP2 were 40% less invasive compared with control cells. 
Since invasive properties are closely related to metastasis, we decided to determine if loss of 
C/EBPβ would influence metastatic capacity of breast cancer cells in vivo. Loss-of-function 
study in 4T1 breast cancer model, driven by TGF-β, resulted in lower E-cadherin expression, 
higher vimentin expression and enhanced invasiveness towards TGF-β1. Tumors of 4T1-
implanted mice grew initially at similar pace to control tumors but their growth rate decreased 
during second week after implantation. Average metastatic foci number in lungs was higher 
in mice carrying C/EBPβ knockdown tumors compared with mice carrying control tumors. 
Moreover, metastasis was found in 100% of mice with C/EBPβ knockdown vs. in only 20% 
of control mice. 
In order to verify the hypothesis that C/EBPβ could regulate the EMT response downstream 
of TGF-β by serving as a transcriptional activator of junction proteins, we firstly used 
computer-based software enabling us to find binding sites for C/EBP transcription factors in 
genomic DNA sequences. Analysis revealed such putative binding sites in promoter regions 
of genes encoding junction proteins such as Cdh1 and Cxadr. ChIP assays confirmed specific 
interactions between C/EBPβ and regions of Cdh1 and Cxadr promoters containing C/EBP 
binding sites in NMuMG cells. We showed that C/EBPβ overexpression activated 
Cdh1 promoter by twofold and the Cxadr promoter by 2.5-fold. While LAP2 was more 
potent compared with C/EBPβ, by activating mentioned promoters by 5- and 4-fold, 
respectively, LIP effect on Cdh1 and Cxadr promoters was scarce. 
In further support to the role of C/EBPβ in maintaining cellular levels of E-cadherin and CAR, 
we showed that knockdown of C/EBPβ led to decreased mRNA levels of Cdh1 and Cxadr. 
What is more, we demonstrated that C/EBPβ dissociated from Cdh1 and Cxadr promoters 
during TGF-β1-induced EMT. 
Presented study suggests that C/EBPβ is able to inhibit EMT and restore the TGF-β response 
towards growth inhibition. Nevertheless, as C/EBPβ failed to fully revert EMT, further studies 
are required to show the role of additional transcription factors in this process. Furthermore, 
C/EBPβ was shown to transcriptionally activate genes encoding the epithelial junctions 
proteins E-cadherin and CAR. Finally, the results identify miR-155-mediated loss of C/EBPβ 
as a mechanism, promoting breast cancer progression by switching the TGF-β response from 
growth inhibition to EMT, invasion and metastasis.  
3.3 STUDY III 
CCAAT-enhancer binding protein β (C/EBPβ) is a transcription factor playing a critical role in 
mammary gland development and breast cancer progression. Our previous study indicated that 
loss of C/EBPβ increases metastatic spreading of mouse mammary tumor cells, but did not 
elucidate the mechanism by which C/EBPβ expression affects metastasis. Therefore, this study 
aimed at explaining C/EBPβ link with metastasis formation and determining the relationship 
between C/EBPβ and survival of breast cancer patients 
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In order to test the hypothesis that C/EBPβ is associated with progression of breast cancer, a 
tissue microarray containing 137 breast cancer patient samples was immunohistochemically 
stained for C/EBPβ. Subsequently, a qualitative scoring of C/EBPβ staining was performed in 
relationship to progression of breast cancer. This descriptive analysis showed that strong 
nuclear positive staining was present in the normal breast tissue as well as in some ductal cancer 
in situ (DCIS). However, C/EBPβ expression in DCIS was lower compared to expression in 
normal breast tissue and in many nodules was mostly present in their basal layer. These nodules 
were surrounded by desmoplastic stroma infiltrated with lymphocytes. Thus, C/EBPβ staining 
intensity was lower in case of inflammation combined with desmoplastic reaction in the tumor 
stroma. This phenomenon was strongly visible particularly in areas of microinvasive cancer. 
The decreased C/EBPβ expression was observed in areas of invasive cancer, especially low in 
areas with strong lymphocytic infiltration. This observation indicates that C/EBPβ might play 
role in progression of breast cancer and appearance of inflammation.  
All samples were analyzed according to 0-2 scale by a pathologist and related to information 
concerning patient survival. Cox proportional hazards models and Kaplan-Meier analysis were 
used to assess the effect of C/EBPβ expression on overall survival (OS) in univariate and 
multivariate analysis, adjusted for established prognostic factors. All parameters were assessed 
in univariate models using Cox proportional hazards models and factors significant at p<0.05 
were included in the final model. In univariate analysis, independent predictors of overall 
survival (OS) were C/EBPβ expression and tumor size. Lack of C/EBPβ expression in patient 
samples was associated with shorter overall survival of breast cancer patients as compared with 
higher C/EBPβ expression. These results indicate that C/EBPβ expression is significantly 
associated with overall survival, but also related to relapse-free survival (RFS). 
In order to study the effect of C/EBPβ on breast cancer, a mouse 4T1 model of breast cancer 
implantation was employed. Two derivatives of 4T1 cells were used – one referred to as sh 
C/EBPβ, expressing wild type C/EBPβ and second one described as sh C/EBPβ, with silenced 
expression of C/EBPβ. Both tumor cell lines were subcutaneously implanted into two groups 
of syngeneic BALB/c mice and subsequently, tumor growth, CTC dissemination and 
metastasis formation was compared between the groups.  
Loss of C/EBPβ expression affected tumor growth, as well as morphology. C/EBPβ-silenced 
tumors grew smaller as compared with non-silenced tumors, even though there was no 
difference in proliferation rate assessed by in vitro assay. This result suggests that tumor growth 
is not directly controlled by C/EBPβ, but rather affected by in vivo factors. Additionally, a 
striking morphological difference was observed between the tumors. While C/EBPβ-
expressing tumors were characterized by large central necrosis, C/EBPβ-silenced tumors 
formed solid tumors with extensive, pushing border growing pattern and inflammation around 
them. 
To further characterize the effect of C/EBPβ on the tumor, tumor vasculature was firstly 
analyzed by immunohistochemical staining for endothelial cell marker CD31. We observed 
more vessels in C/EBPβ-silenced tumors as compared with non-silenced tumors. 
The study of the tumor vasculature was followed by whole mount immunohistochemistry on 
tumors, which were stained for both CD31 and a pericyte marker NG2. Subsequently, results 
were analyzed by Visiopharm software. Despite previous results concerning differences in 
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vessel number, no significant differences in vessel morphology were found, when assessing 
features such as vessel length, area, pericyte coverage of the vessels and number of 
branchpoints, which were similar in both groups. 
To study the effect of C/EBPβ on tumor spreading and formation of metastasis, focus was put 
on the presence of CTCs in blood and bone marrow and appearance of metastatic nodules in 
the distant organs. In this model, the cells were labeled with EGFP, what allowed for 
calculating the number of CTC in blood and bone marrow. No statistically significant 
differences in number of CTC in blood and bone marrow between sh control and sh C/EBPβ 
tumors were observed at the endpoint of the experiment (2 months following primary tumor 
excision). 
Next, morphological analysis of the lungs of tumor-bearing mice was performed to study if 
C/EBP knockdown affected metastatic spread. The ratio of mice with lung metastasis/without 
metastasis was significantly higher in mice carrying C/EBP knockdown versus control 4T1 
tumors, what indicated that loss of C/EBP promotes metastatic spread of mammary 4T1 
tumors. Moreover, morphological analysis showed that lungs of mice carrying C/EBP 
knockdown had more prominent chronic inflammation versus lungs of C/EBP-expressing 
mice. This observation is in agreement with the fact that C/EBP affects formation of 
inflammatory process, as was already found in human TMA analysis.  
To unravel the mechanism of how C/EBP affects formation of metastasis, a microarray 
analysis was performed by using RNA extracts from 4T1 cells expressing C/EBP shRNA or 
control shRNA. Gene profiling revealed a set of 559 genes that were statistically different 
between sh control and sh C/EBP cells. Analysis done by Panther DB service indicates that 
inflammatory group of genes was the most significant among all genes. Thus, as shown on Fig. 
4A, main focus was put to analysis of these genes. Representative genes included MHCIIα, 
MHCIIβ and HLACIIγ. Additionally, chemokines were also affected, such as CCL5, CCL7 
and CCL8.   
To follow the chemokines analysis, the cells were further analyzed by chemokine protein array, 
which did not confirm previous finding. However, many other chemokines were upregulated 
in the sh C/EBP  cells as compared with sh control cells, such as CCL2, CCL6, CCL12, 
CCL27, CCL28, chemerin, CXCL16 and IL-16. 
To find if a similar pattern of differences could be observed in the tumor, the tumors dissected 
from mice were also profiled by microarray analysis, using RNA extracts from 4T1 tumors 
expressing C/EBP shRNA, or control tumors shRNA. In this setup only 135 genes were 
upregulated more than 1.3 fold. The results were further processed with Panther DB service 
and in this case, immunological group of genes was also the most representative. Many of the 
genes on this list are still uncharacterized and have unknown function, however it is striking 
that CD3+ leukocytes were first on the list with difference equal 5 times fold.  These results 
clearly show that C/EBPβ is involved in modulation of immunological response in the tumors.  
Taken altogether, the results of human breast cancer study, morphological analysis of mouse 
tissue and tumor growth supported the microarray data and suggested that C/EBP is involved 
in metastatic process by controlling the expression of a set of genes involved in inflammatory 
formation. To confirm this finding, sh C/EBPβ tumors and sh control tumors were stained for 
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CD45, CD3, CD4 and MHCII. The analysis showed that the inhibition of C/EBPβ leads to an 
increased expression of MHCII followed by accumulation of CD45, CD3 and CD4-positive 
lymphocytes in the tumors. This was the most striking and significant difference between the 
tumors as shown by morphological, microarray data and immunohistochemical analysis.  
To study, if the effect of C/EBPβ on tumor growth and metastasis can be reversed by specific 
treatment, BALB/c mice bearing sh C/EBPβ tumors were treated with anti-CD3 or anti-CD4 
antibodies. The results have shown that sh C/EBPβ tumors grew much bigger when treated 
with either CD3 or CD4 antibodies as compared with non-treated sh C/EBPβ tumors, even 
though normally C/EBPβ knockdown decreases tumor growth. Moreover, the treatment led to 
diminishing the differences in tumor morphology. Although no effect of treatment on the 
number of CTCs in the blood or bone marrow was observed in this model, the experiment 
confirmed involvement of CD4 T-cells in C/EBPβ-dependent tumor growth. Similar 
conclusion was drawn from a study in T-cell deprived nude mice, which have no CD3 and CD4 
cells at time of experiment, where C/EBPβ-silenced tumors grew bigger than non-silenced 
tumors. What is more, both groups had similar ratio of lung metastasis, what shows that in this 
model, C/EBPβ effect on metastasis formation was attenuated as compared with experiment 
on immunocompetent mice. 
To summarize the results of presented study, C/EBPβ is a predictor of overall survival in breast 
cancer patients, and affects tumor growth, morphology and lung metastasis formation in murine 
4T1 breast cancer model. The mechanism of metastasis formation is associated with 
immunological response, which depends on C/EBPβ-mediated activation of MHCII and CD4+ 
lymphocytes. 
3.4 STUDY IV 
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Since in 
most of the cases liver metastasis is responsible for the patient mortality, a significant effort 
needs to be done to recognize factors controlling metastatic process, what would contribute 
to improving future patient therapies. Presented study identified CCL7 chemokine as one of 
such factors and aimed at studying CCL7 role in colon cancer progression in vivo. Moreover, 
human tissue microarray (TMA) was used to determine associations between expression of 
CCL7 receptors and clinical data from colorectal cancer patients. 
In our study, we firstly analyzed crosstalk between murine MSCs and colon colon carcinoma 
CT26 cells in vitro. We showed that CT26 cells have higher proliferation rate, when 
cocultured in direct contact with MSCs after 24, 48 and 72h. Interestingly, CT26 proliferation 
rate was not affected when cells were cocultured with MSCs in transwell setting or subject 
to MSC-conditioned media. Additionally, we demonstrated increased migratory properties 
of CT26 cells stimulated with MSCs as chemoattractant. 
Subsequently, DNA microarray was employed to find the differences in chemokines and their 
receptors expression between MSCs and CT26 cells. We showed that these cells differ in 
terms of chemokines and chemokine receptor expression patterns. We observed that CCL7 
expression was upregulated, while CCR1 expression, which is CCL7 receptor, was 
downregulated in MSCs vs. CT26 cells. Moreover, similar results concerning CCL7 and 
CCR1 were obtained by PCR array analysis using cocultured CT26+MSCs compared to 
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CT26 cells. Next, ELISA was done to confirm obtained results on protein level. Analysis 
revealed that MSCs cocultured with CT26 cells in transwell system had significantly higher 
concentration of CCL7 compared with MSCs in monoculture. Additionally, ELISA showed 
that CT26+MSC coculture secreted more CCL7 compared to CT26. 
To check if recombinant CCL7 affects proliferation rate of CT26 cells in vitro, we performed 
MTT proliferation assay. However, none of studied concentrations of CCL7 led to a change 
in proliferation rate of CT26 cells. Afterwards, with use of lentiviral transduction, we created 
a CT26-derived cell line overexpressing CCL7, called mCCL7+, and a control cell line, 
called blank control. CCL7 overexpression in mCCL7+ cells vs blank control cells was 
confirmed by ELISA. Comparison of produced cell lines showed no difference in 
proliferation rates, what once more confirmed that CCL7 has no effect on proliferation of 
CT26 cells in vitro. Surprisingly, scratch assay did not show difference in migration between 
compared cell lines. 
In order to assess effect of CCL7 overexpression on tumor development in vivo, blank control 
or mCCL7+ cells were injected subcutaneously into mice. Study revealed that mCCL7+ cell 
implantation led to acceleration in the early phase of tumor growth (between day 5 to day 11), 
when mCCL7+ tumor-bearing mice had larger tumors compared with blank control-injected 
mice. Nevertheless, already 11 days post-implantation tumors continued to grow in a similar 
pace in both groups. 
Morphological analysis of the isolated tumors showed no striking differences between the two 
tumor types. However, analysis of murine lungs isolated two months after tumor excision 
revealed that mCCL7+ cell line injection resulted in increased lung metastasis by 33% in 
comparison with control mice. This observation indicated that overexpression of CCL7 
stimulates metastatic dissemination of CT26 tumors to the lungs. In addition, lungs from 
CCL7-overexpressing tumor-bearing mice had extensive intra-alveolar bleedings, absent in 
blank control-implanted mice. 
Next, real time PCR was performed in order to determine and compare expression levels of 
CCL7 receptors (CCR1, CCR2 and CCR3) in blank control, as well as mCCL7+ cell line. We 
found that the level of CCR1 mRNA was lower by almost 30% in mCCL7+ cells compared 
with blank control cells. On the other hand, the level of CCR2 mRNA was almost two times 
higher in mCCL7+ cells compared with blank control cells. Additionally, no CCR3 mRNA 
was detected, what suggested that the analyzed cell types express only CCR1 and CCR2. 
Finally, in order to assess the relationship between CCL7 receptor expression and clinical 
patient data, a tissue microarray (TMA) containing colorectal cancer patient samples was 
immunohistochemically stained for CCL7 receptors (CCR1, CCR2 and CCR3). Analysis 
performed by pathologist revealed different grades of expression of CCL7 receptors, assessed 
as low or high. Descriptive data analysis showed that 73% of patients who developed lymph 
node metastases, had high expression of CCR2, compared with only 27% of metastasis-
positive patients having lower CCR2 expression. Moreover, high CCR2 expression in analyzed 
patient samples was associated with shorter relapse-free survival (RFS) of colorectal cancer 
patients compared with low expression of CCR2. In addition, high CCR2 expression was 
associated with shorter overall survival (OS) of colorectal cancer patients compared with low 
CCR2 expression, what was subsequently confirmed by Kaplan-Meier analysis. To sum up, 
obtained results indicate that high CCR2 expression is significantly associated with OS of 
colorectal cancer patients. In contrast, no associations of CCR1 or CCR3 with patient survival 
were found. 
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Altogether, presented study indicates that overexpression of CCL7 affects early phase of 
tumor growth and lung metastasis in mouse CT26 colon cancer model and CCR2, as a CCL7 
receptor, predicts overall survival of colorectal cancer patients. However, additional work 
needs to be done in order to discover the mechanism, through which CCL7 regulates 
metastasis formation and to confirm the role of CCR2-CCL7 axis in this process. 
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4 CONCLUSIONS 
Mesenchymal stem cells and their role in blood vessel formation have been widely discussed 
in vascular biology field. In study I, we identified MSCs derived from adventitia as a source 
of cells which contribute to intimal hyperplasia. Specifically, CD90+, CD44+ and sca-1+ cells 
were dominant subpopulations of MSCs that migrated towards the intima. Moreover, these 
cells expressed CCR2, a receptor for MCP-1, which was the most potent chemokine 
controlling migration of analyzed MSCs. This study not only confirmed the presence of 
MSCs in the blood vessels, but also explained their role in intimal hyperplasia, what 
contributes to better understanding of this process. 
Apart from their function in vascular formation and remodeling, MSCs have an important 
role in tumor progression. However, their impact on this process still remains  controversial. 
In study IV, we analyzed the crosstalk between MSCs and colon cancer. In vitro studies 
showed that MSCs increase proliferation rate, as well as migration of mouse CT26 colon 
carcinoma cells. Moreover, multiple crosstalk analyses revealed MSCs have higher 
expression of CCL7 chemokine, compared with CT26 cells. Also, cocultured CT26+MSC 
secrete more CCL7, when compared with CT26 or MSCs in monoculture. Subsequent in vivo 
experiments showed that overexpression of CCL7 quickens the early phase of tumor growth 
and leads to higher lung metastasis rate in tumor-bearing mice compared to control mice. 
This observation indicates that CCL7 affects lung metastasis. However, the mechanism 
behind that relationship remains to be elucidated. Additionally, we identified CCR2 as CCL7 
receptor that predicts overall survival of colorectal cancer patients. Namely, higher 
expression of CCR2 was associated with shorter OS. Further studies need to be performed in 
order to confirm the role of CCR2-CCL7 axis in metastasis formation and its link to survival 
of the patients. 
Tumor progression is a complicated process regulated by several various factors, such as 
C/EBPβ transcription factor. In study II we analyzed the relationship between EMT and 
C/EBPβ expression in breast cancer. Human samples analysis demonstrated that lower C/EBPβ 
expression was associated with triple-negative tumors and mouse experiment confirmed that 
loss of C/EBPβ was observed in E-cadherin-negative areas of the tumors. We showed that miR-
155-mediated loss of C/EBPβ was specifically associated with EMT. Moreover, silenced 
expression of C/EBPβ in breast cancer cells led to higher invasiveness and lung metastasis in 
tumor-bearing mice compared to control mice. In addition, C/EBPβ was demonstrated to be 
transcriptional activator o genes encoding epithelial junctions proteins (E-cadherin and CAR). 
Described study suggests that C/EBPβ can inhibit EMT and restore response of TGF-β towards 
growth inhibition. Nonetheless, deeper studies are needed to show the function of additional 
factors in this process, as C/EBPβ was not able to fully revert EMT on its own.  
Study III focused on the role of C/EBPβ in metastasis formation and its effect on tumor 
morphology. Firstly, we identified  C/EBPβ as a predictor of OS of breast cancer patients. 
Secondly, in vivo analysis showed that loss of C/EBPβ affects tumor growth and morphology 
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in mouse 4T1 breast cancer model. Namely, C/EBPβ-silenced cells caused formation of smaller 
in size, yet intact and well vascularized tumors, compared to bigger, but necrosis-containing 
control tumors. Furthermore, C/EBPβ knockdown promoted lung metastasis formation by 
triggering inflammation. Specifically, inflammatory response was triggered through MHCII 
activation and accumulation of CD4+ lymphocytes in the sh C/EBPβ tumors. Finally, blocking 
CD4-mediated inflammation in 4T1 mice attenuated the effect of C/EBPβ on tumor growth, 
morphology and metastasis formation. Presented study not only found a new predictive factor 
for OS of breast cancer patients, but also provided new insights on effect of C/EBPβ on breast 
cancer progression. 
Both regenerative medicine and cancer field need new therapy targets, as well as predictive 
factors. This work not only contributed to broadening the knowledge about role of 
mesenchymal stem cells in vascular structure and remodeling, but also shed new light on 
C/EBPβ as a factor affecting metastasis, tumor growth and morphology. Moreover, C/EBPβ 
was identified as a predictor of overall survival in breast cancer patients, while CCL7, in 
colorectal cancer patients, what has high importance for clinical oncology.  
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